Gloria Leva

Gloria Leva

Auto-generated profile, based on publicly available information

Gloria Leva

Department CIBIO, University of Trento, Trento, Italy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2023 in EMBO Molecular Medicine
Verified
Journal Article
Open access
CLChiara Lago
Chiara Lago
AFAniello Federico
Aniello Federico
GLGloria Leva
Gloria Leva
NMNorman L Mack
Norman L Mack
BSBenjamin Schwalm
Benjamin Schwalm
LTLuca Tiberi
Luca Tiberi
Brain tumors are the leading cause of cancer‐related death in children. Experimental in vitro models that faithfully capture the hallmarks and tumor heterogeneity of pediatric brain cancers are limited and hard to establish. We present a protocol that enables efficient generation, expansion, and biobanking of pediatric brain cancer organoids. Utilizing our protocol, we have established patient‐derived organoids (PDOs) from ependymomas, medulloblastomas, low‐grade glial tumors, and patient‐derived xenograft organoids (PDXOs) from medulloblastoma xenografts. PDOs and PDXOs recapitulate histological features, DNA methylation profiles, and intratumor heterogeneity of the tumors from which they were derived. We also showed that PDOs can be xenografted. Most interestingly, when subjected to the same routinely applied therapeutic regimens, PDOs respond similarly to the patients. Taken together, our study highlights the potential of PDOs and PDXOs for research and translational applications for personalized medicine.

29 May 2023 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
CLChiara Lago
Chiara Lago
MGMatteo Gianesello
Matteo Gianesello
LSLucia Santomaso
Lucia Santomaso
GLGloria Leva
Gloria Leva
CBClaudio Ballabio
Claudio Ballabio
LTLuca Tiberi
Luca Tiberi

30 March 2026 in Nature Protocols
Verified
Journal Article
Closed access
CLChiara Lago
Chiara Lago
GLGloria Leva
Gloria Leva
MKMarcel Kool
Marcel Kool
Evelina MieleEvelina Miele
Evelina Miele
LTLuca Tiberi
Luca Tiberi

21 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
JCjulie contenti
julie contenti
YGYingbo Guo
Yingbo Guo
MLMagalie Larcher
Magalie Larcher
LMLiliana Mirabal-Ortega
Liliana Mirabal-Ortega
MRMatthieu Rouleau
Matthieu Rouleau
NMNathalie M Mazure
Nathalie M Mazure
Medulloblastoma (MB) is the most prevalent brain cancer in children. Four subgroups of MB have been identified; of these, Group 3 is the most metastatic. Its genetics and biology remain less clear than the other groups, and it has a poor prognosis and few effective treatments available. Tumor hypoxia and the resulting metabolism are known to be important in the growth and survival of tumors but, to date, have been only minimally explored in MB. Here we show that Group 3 MB tumors do not depend on the canonical transcription factor hypoxia-inducible factor-1α (HIF-1α) to mount an adaptive response to hypoxia. We discovered that HIF-1α is rendered inactive either through post-translational methylation, preventing its nuclear localization specifically in Group 3 MB, or by a low expression that prevents modulation of HIF-target genes. Strikingly, we found that HIF-2 takes over the role of HIF-1 in the nucleus and promotes the activation of hypoxia-dependent anabolic pathways. The exclusion of HIF-1 from the nucleus in Group 3 MB cells enhances the reliance on HIF-2’s transcriptional role, making it a viable target for potential anticancer strategies. By combining pharmacological inhibition of HIF-2α with the use of metformin, a mitochondrial complex I inhibitor to block respiration, we effectively induced Group 3 MB cell death, surpassing the effectiveness observed in Non-Group 3 MB cells. Overall, the unique dependence of MB cells, but not normal cells, on HIF-2-mediated anabolic metabolism presents an appealing therapeutic opportunity for treating Group 3 MB patients with minimal toxicity.